Upgrade to SI Premium - Free Trial

Pacira Pharma (PCRX): AdComm Votes 6:4 No for Nerve Block sNDA Approval, PT To $72 - Wedbush

February 16, 2018 7:04 AM
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and cut her price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles